| Sialorrhea

Cuvposa vs Myobloc

Side-by-side clinical, coverage, and cost comparison for sialorrhea.

Deep comparison between: Cuvposa vs Myobloc with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsMyobloc has a higher rate of injection site reactions vs Cuvposa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Myobloc but not Cuvposa, including UnitedHealthcare

Category

Cuvposa

Myobloc

At A Glance

RouteOral

FrequencyThree times daily

ClassAnticholinergic

RouteIM/intraglandular injection

FrequencyEvery 12-16 weeks

ClassBotulinum toxin type B

Indications

Sialorrhea

Isolated cervical dystonia
Sialorrhea

Dosing

Sialorrhea Initiate at 0.02 mg/kg orally three times daily; titrate in 0.02 mg/kg increments every 5-7 days based on response and tolerability; maximum 0.1 mg/kg three times daily, not to exceed 1.5-3 mg per dose based on weight; administer at least 1 hour before or 2 hours after meals.

Isolated cervical dystonia 2,500 to 5,000 Units divided among affected muscles by IM injection in patients with prior botulinum toxin tolerance; effects typically last 12-16 weeks.

Sialorrhea 1,500 to 3,500 Units total by intraglandular injection: 500-1,500 Units per parotid gland and 250 Units per submandibular gland; no more frequent than every 12 weeks.

Contraindications

Medical conditions that preclude anticholinergic therapy (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis)
Concomitant use of solid oral dosage forms of potassium chloride

Known hypersensitivity to any botulinum toxin product or to any component of the formulation
Infection at the proposed injection site(s)

Drug Interactions

254View drug interactions

341View drug interactions

Adverse Reactions

Most common (>=15%) Dry mouth, vomiting, constipation, flushing, nasal congestion, headache, sinusitis, upper respiratory tract infection, urinary retention

Serious Constipation or intestinal pseudo-obstruction, incomplete mechanical intestinal obstruction

Postmarketing Loss of taste, suppression of lactation

Most common (>=5%) Dry mouth, dysphagia, injection site pain, headache, dyspepsia, flu syndrome, back pain, arthralgia, dizziness, asthenia.

Serious Severe dysphagia, severe dry mouth; both most frequent adverse reactions leading to treatment discontinuation.

Postmarketing Angioedema, urticaria, rash, constipation, dry eye, accommodation disorder.

Pharmacology

Glycopyrrolate is a competitive inhibitor of acetylcholine receptors on peripheral tissues including salivary glands, indirectly reducing salivation by preventing stimulation of these receptors.

RimabotulinumtoxinB is a botulinum toxin type B that blocks cholinergic transmission at neuromuscular and salivary neuroglandular junctions by inhibiting acetylcholine release via enzymatic cleavage of synaptobrevin (VAMP), a presynaptic protein essential for vesicle fusion; nerve terminal function is restored by formation of new nerve endings.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cuvposa